Polatuzumab vedotin 30mg powder for solution for infusion vials
NHS hospitals in England used £17,653,324 of indicative cost of Polatuzumab vedotin 30mg powder for solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 4.3% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Polatuzumab vedotin 30mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Polatuzumab vedotin 30mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Royal Devon & Exeter Nhs Foundation Trst | £914,725 |
| Barts Health Nhs Trust | £774,990 |
| York Teaching Hospital Nhs Ft | £713,370 |
| University Hpls Of Leicester Nhs Trust | £673,080 |
| Calderdale & Huddersfield Nhs Found Tr | £654,120 |
| University Hospitals Dorset Nhs Ft | £620,940 |
| Maidstone And Tunbridge Wells Nhs Trust | £597,240 |
| Royal Free London Nhs Foundation Trust | £587,428 |
| The Clatterbridge Cancer Centre Nhs Ft | £571,170 |
| Somerset P/Ship Nhs Foundation Trust | £566,430 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.